Allergic Conjunctivitis: Clinical Trials

41 trials for Allergic Conjunctivitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

41 completed. 41 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 341Completed 41
Phase 21Completed 1

Follow Allergic Conjunctivitis: new trials by email Literature Review of Allergic Conjunctivitis trials Research Report on Allergic Conjunctivitis

Trials (filtered) newest first · largest first

All 41 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
REGN5713, REGN5715, Placebo - Allergic Conjunctivitis
Phase 3CompletedRegeneron Pharmaceuticals542024-11-192026-04-21
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
REGN1908, REGN1909, Placebo - Allergic Conjunctivitis
Phase 3CompletedRegeneron Pharmaceuticals642024-11-062026-05-08
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution - Allergic Conjunctivitis
Phase 3CompletedBausch & Lomb Incorporated5122023-04-202025-07-10
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035% - Allergic Conjunctivitis
Phase 3CompletedBausch & Lomb Incorporated1882022-10-122025-02-14
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis
Phase 3CompletedAldeyra Therapeutics, Inc.1312022-01-212026-05-14
Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
Bilastine, Placebo - Allergic Conjunctivitis
Phase 3CompletedFaes Farma, S.A.592021-03-262023-03-16
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis
Phase 3CompletedAldeyra Therapeutics, Inc.952019-12-052024-11-20
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
Dexamethasone, 0.4mg, Placebo plug with no drug - Allergic Conjunctivitis
Phase 3CompletedOcular Therapeutix, Inc.962019-08-052021-10-07
Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray
Rhinocort, Budesolv, Placebo - Allergic Rhinitis, Allergic Conjunctivitis
Phase 3CompletedMarinomed Biotech AG822018-11-192020-10-12
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution - Allergic Conjunctivitis
Phase 3CompletedFaes Farma, S.A.2282018-04-072023-03-16
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
EM-100, Zaditor®, Vehicle - Allergic Conjunctivitis
Phase 3CompletedBausch & Lomb Incorporated652018-04-072023-06-08
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis
Phase 3CompletedAldeyra Therapeutics, Inc.3182018-03-302025-02-11
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle - Allergic Conjunctivitis
Phase 3CompletedAlcon Research3832014-12-012017-11-17
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
AC-170 0.24%, AC-170 0% - Allergic Conjunctivitis
Phase 3CompletedAciex Therapeutics, Inc.1012013-06-012017-11-09
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
AL-4943A ophthalmic solution, Olopatadine hydrochloride ophthalmic solution, 0.2%, Olopatadine hydrochloride ophthalmic solution, 0.1% - Allergic Conjunctivitis
Phase 3CompletedAlcon Research9022013-01-012014-08-11
A Six-Week Safety Study of an Investigational Ophthalmic Solution
AL-4943A Ophthalmic Solution, AL-4943A Ophthalmic Solution Vehicle - Allergic Conjunctivitis
Phase 3CompletedAlcon Research5182012-10-012014-03-27
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
AC-170 0.24%, AC-170 0% - Allergic Conjunctivitis
Phase 3CompletedAciex Therapeutics, Inc.1002012-09-012017-10-10
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
AC-170 0.24%, AC-170 0% - Allergic Conjunctivitis
Phase 3CompletedAciex Therapeutics, Inc.912012-03-012017-11-07
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
AKF-1 - Allergic Conjunctivitis
Phase 3CompletedAkorn, Inc.902012-03-012013-07-18
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
AL-4943A ophthalmic solution, AL-4943A vehicle, Olopatadine hydrochloride ophthalmic solution, 0.2% - Allergic Conjunctivitis
Phase 3CompletedAlcon Research3972012-01-012013-06-04

Showing 20 of 41. Sign in to see all of them.

Narrower conditions

Conjunctivitis, Allergic (41)  ·  Hypersensitivity (3)  ·  Rhinitis, Allergic (2)  ·  Rhinitis, Allergic, Seasonal (2)  ·  Nasal Obstruction (1)

Broader conditions

Conjunctival Diseases (41)  ·  Conjunctivitis (41)  ·  Eye Diseases (41)  ·  Hypersensitivity, Immediate (41)  ·  Immune System Diseases (41)  ·  Hypersensitivity (38)  ·  Nose Diseases (2)  ·  Otorhinolaryngologic Diseases (2)  ·  Respiratory Hypersensitivity (2)  ·  Respiratory Tract Diseases (2)  ·  Rhinitis (2)  ·  Airway Obstruction (1)  ·  Respiration Disorders (1)  ·  Respiratory Insufficiency (1)

Interventions

Ketotifen (6)  ·  Olopatadine Hydrochloride (6)  ·  Ophthalmic Solutions (3)  ·  Brimonidine Tartrate (2)  ·  Naphazoline (2)  ·  bepotastine besilate (2)  ·  Budesonide (1)  ·  Contact Lenses (1)  ·  Dexamethasone (1)  ·  alcaftadine (1)  ·  bilastine (1)  ·  bromfenac (1)  ·  ketotifen fumarate ophthalmic solution (1)

Sponsors

Bausch & Lomb Incorporated (9)  ·  Vistakon Pharmaceuticals (8)  ·  Alcon Research (7)  ·  Aciex Therapeutics, Inc. (4)  ·  Aldeyra Therapeutics, Inc. (3)  ·  Faes Farma, S.A. (2)  ·  Regeneron Pharmaceuticals (2)  ·  Santen Pharmaceutical Co., Ltd. (2)  ·  Akorn, Inc. (1)  ·  Marinomed Biotech AG (1)  ·  Ocular Therapeutix, Inc. (1)  ·  Stallergenes Greer (1)

Countries

United States (25)  ·  Canada (4)  ·  Japan (3)  ·  Austria (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Estonia (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Latvia (1)  ·  Lithuania (1)  ·  Poland (1)  ·  Slovakia (1)  ·  Spain (1)

Top investigators

Brian Pall, OD, MS, FAAO (4)  ·  Abhijit Narvekar, MS, MBBS (2)  ·  Edward Meier, MD (2)  ·  Ingerman Avner, MD (2)  ·  Stacey Ackerman, MD (2)  ·  Tim McNamara, PharmD (2)  ·  Dawn DeCastro, MD (1)  ·  Eugene McLaurin, MD (1)  ·  Eugene Protzko, MD (1)  ·  Eva E Prieschl-Grassauer, PhD (1)  ·  Gail L Torkildsen, MD (1)  ·  Gail Torkildsen (1)  ·  Jack Greiner, DO (1)

Results publications

PMID 27466061, PMID 20488431, PMID 21250860, PMID 22991696, PMID 24517417, PMID 25163405, PMID 26266427, PMID 36811846, PMID 38105911, PMID 39328900

NIH funding

2016 (1), 2018 (1)